Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketobemidone is a powerful synthetic opioid analgesic of the phenylpiperidine class, used primarily for the management of severe pain. Its analgesic potency is comparable to morphine. In addition to its action as an agonist at mu-, kappa-, and delta-opioid receptors, it also exhibits N-methyl-D-aspartate (NMDA) receptor antagonist properties, which may contribute to its effectiveness in certain types of pain that are resistant to other opioids. The drug undergoes hepatic metabolism mainly via glucuronidation and N-demethylation pathways, with possible involvement of CYP3A4 enzymes. It is marketed in several Scandinavian countries for severe pain but has been withdrawn from some markets such as Sweden[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketobemidone.